<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33117346</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>A Polysaccharide Purified From <i>Ganoderma lucidum</i> Acts as a Potent Mucosal Adjuvant That Promotes Protective Immunity Against the Lethal Challenge With Enterovirus A71.</ArticleTitle><Pagination><StartPage>561758</StartPage><MedlinePgn>561758</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">561758</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.561758</ELocationID><Abstract><AbstractText>Enterovirus A71 (EV-A71), the pathogen responsible for the seasonal hand-foot-and-mouth epidemics, can cause significant mortality in infants and young children. The vaccine against EV-A71 could potentially prevent virus-induced neurological complications and mortalities occurring due to the high risk of poliomyelitis-like paralysis and fatal encephalitis. It is known that polysaccharide purified from <i>Ganoderma lucidum</i> (PS-G) can effectively modulate immune function. Here, we used PS-G as an adjuvant with the EV-A71 mucosal vaccine and studied its effects. Our data showed that PS-G-adjuvanted EV-A71 generated significantly better IgA and IgG in the serum, saliva, nasal wash, bronchoalveolar lavage fluid (BALF), and feces. More importantly, these antibodies could neutralize the infectivity of EV-A71 (C2 genotype) and cross-neutralize the B4, B5, and C4 genotypes of EV-A71. In addition, more EV-A71-specific IgA- and IgG- secreting cells were observed with the used of a combination of EV-A71 and PS-G. Furthermore, T-cell proliferative responses and IFN-&#x3b3; and IL-17 secretions levels were notably increased in splenocytes when the EV-A71 vaccine contained PS-G. We also found that levels of IFN-&#x3b3; and IL-17 released in Peyer's patch cells were significantly increased in EV-A71, after it was combined with PS-G. We further demonstrated that both CD4<sup>+</sup> and CD8<sup>+</sup> T cells were able to generate IFN-&#x3b3; and IL-17 in the spleen. An easy-accessed model of hybrid hSCARB2<sup>+</sup>/<sup>+</sup>/stat-1<sup>-</sup>/<sup>-</sup> mice was used for EV-A71 infection and pathogenesis. We infected the mouse model with EV-A71, which was premixed with mouse sera immunized with the EV-A71 vaccine with or without PS-G. Indeed, in the EV-A71 + PS-G group, the levels of VP1-specific RNA sequences in the brain, spinal cord, and muscle decreased significantly. Finally, hSCARB2-Tg mice immunized via the intranasal route with the PS-G-adjuvanted EV-A71 vaccine resisted a subsequent lethal oral EV-A71 challenge. Taken together, these results demonstrated that PS-G could potentially be used as an adjuvant for the EV-A71 mucosal vaccine.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Lin, Shih, Cheng, Chin, Liou, Lee and Chiang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Chiaho</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Pei-Yun</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Chiao-Li</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liou</LastName><ForeName>An-Ting</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Po-Yi</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Good Health Food Co., Ltd., Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Bor-Luen</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062610">Fungal Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048690" MajorTopicYN="N">Fruiting Bodies, Fungal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062610" MajorTopicYN="N">Fungal Polysaccharides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020940" MajorTopicYN="N">Reishi</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">IFN-&#x3b3;</Keyword><Keyword MajorTopicYN="N">IL-17</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">intranasal</Keyword><Keyword MajorTopicYN="N">mucosal vaccine</Keyword><Keyword MajorTopicYN="N">polysaccharide from Ganoderma lucidum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33117346</ArticleId><ArticleId IdType="pmc">PMC7550786</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2020.561758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol. (2010) 84:3339&#x2013;50. 10.1128/JVI.01019-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. (2003) 9:461&#x2013;8. 10.3201/eid0904.020395</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0904.020395</ArticleId><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. (2008) 7:868&#x2013;9. 10.1016/S1474-4422(08)70207-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70207-2</ArticleId><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. (2002) 26:91&#x2013;107. 10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Oberste MS, Alexander JP, Jr., Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol. (1999) 73:9969&#x2013;75. 10.1128/JVI.73.12.9969-9975.1999</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.12.9969-9975.1999</ArticleId><ArticleId IdType="pmc">PMC113047</ArticleId><ArticleId IdType="pubmed">10559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. (1995) 39:195&#x2013;205. 10.1016/0168-1702(95)00087-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg Infect Dis. (2003) 9:291&#x2013;3. 10.3201/eid0903.020285</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0903.020285</ArticleId><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Tsao KC, Hsia SH, Shih SR, Huang CG, Chan WK, et al. Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA. (2004) 291:222&#x2013;7. 10.1001/jama.291.2.222</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.291.2.222</ArticleId><ArticleId IdType="pubmed">14722149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY. Enterovirus 71 infection and neurological complications. Korean J Pediatr. (2016) 59:395&#x2013;401. 10.3345/kjp.2016.59.10.395</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2016.59.10.395</ArticleId><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. (2009) 15:798&#x2013;801. 10.1038/nm.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Fujii K, Koike S. Receptors for enterovirus 71. Emerg Microbes Infect. (2014) 3:e53. 10.1038/emi.2014.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.49</ArticleId><ArticleId IdType="pmc">PMC4126179</ArticleId><ArticleId IdType="pubmed">26038749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritsch A, Tancevski I, Schgoer W, Pfeifhofer C, Gander R, Eller P, et al. Molecular characterization of rabbit scavenger receptor class B types I and II: portal to central vein gradient of expression in the liver. J Lipid Res. (2004) 45:214&#x2013;22. 10.1194/jlr.M300353-JLR200</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M300353-JLR200</ArticleId><ArticleId IdType="pubmed">14595001</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Koike S. Identification of a human SCARB2 region that is important for enterovirus 71 binding and infection. J Virol. (2011) 85:4937&#x2013;46. 10.1128/JVI.02358-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02358-10</ArticleId><ArticleId IdType="pmc">PMC3126200</ArticleId><ArticleId IdType="pubmed">21389126</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol. (2012) 86:5686&#x2013;96. 10.1128/JVI.00020-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00020-12</ArticleId><ArticleId IdType="pmc">PMC3347270</ArticleId><ArticleId IdType="pubmed">22438546</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol. (2013) 87:3335&#x2013;47. 10.1128/JVI.02070-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02070-12</ArticleId><ArticleId IdType="pmc">PMC3592140</ArticleId><ArticleId IdType="pubmed">23302872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA. (2013) 110:14753&#x2013;8. 10.1073/pnas.1217563110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1217563110</ArticleId><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li JX, Jin PF, Wang YX, Zhu FC. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev Vaccines. (2016) 15:803&#x2013;13. 10.1080/14760584.2016.1191357</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2016.1191357</ArticleId><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. (2012) 12:592&#x2013;605. 10.1038/nri3251</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3251</ArticleId><ArticleId IdType="pubmed">22828912</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants&#x2013;a brief overview. Immunol Lett. (2010) 128:29&#x2013;35. 10.1016/j.imlet.2009.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2009.10.005</ArticleId><ArticleId IdType="pmc">PMC2999744</ArticleId><ArticleId IdType="pubmed">19895847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell&#x2019;s palsy in Switzerland. N Engl J Med. (2004) 350:896&#x2013;903. 10.1056/NEJMoa030595</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030595</ArticleId><ArticleId IdType="pubmed">14985487</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll H. Dendritic cells as a tool to combat infectious diseases. Immunol Lett. (2003) 85:153&#x2013;7. 10.1016/S0165-2478(02)00222-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-2478(02)00222-5</ArticleId><ArticleId IdType="pubmed">12527222</ArticleId></ArticleIdList></Reference><Reference><Citation>Adema GJ. Dendritic cells from bench to bedside and back. Immunol Lett. (2009) 122:128&#x2013;30. 10.1016/j.imlet.2008.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2008.11.017</ArticleId><ArticleId IdType="pubmed">19121337</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev. (2009) 61:177&#x2013;97. 10.1124/pr.109.001073</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.109.001073</ArticleId><ArticleId IdType="pmc">PMC2846156</ArticleId><ArticleId IdType="pubmed">19474110</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki T, Nishijima M. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem Pharm Bull. (1981) 29:3611&#x2013;6. 10.1248/cpb.29.3611</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.29.3611</ArticleId><ArticleId IdType="pubmed">7340947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang QH, Hu QX, Xie D, Chang B, Miao HG, Wang YG, et al. Ganoderma lucidum exerts an anticancer effect on human osteosarcoma cells via suppressing the wnt/beta-catenin signaling pathway. Integr Cancer Ther. (2019) 18:1534735419890917. 10.1177/1534735419890917</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1534735419890917</ArticleId><ArticleId IdType="pmc">PMC6923688</ArticleId><ArticleId IdType="pubmed">31855073</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. (1997) 70:699&#x2013;705. 10.1002/(sici)1097-0215(19970317)70:63.0.co;2-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0215(19970317)70:63.0.co;2-5</ArticleId><ArticleId IdType="pubmed">9096652</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Su L, Li D, Shuai O, Zhang Y, Liang H, et al. Antitumor activity of extract from the sporoderm-breaking spore of Ganoderma lucidum: restoration on exhausted cytotoxic T cell with gut microbiota remodeling. Front Immunol. (2018) 9:1765. 10.3389/fimmu.2018.01765</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01765</ArticleId><ArticleId IdType="pmc">PMC6079217</ArticleId><ArticleId IdType="pubmed">30108589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liang YC, Lee SS, Chiang BL. Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and p38 mitogen-activated protein kinase pathways. J Leukoc Biol. (2005) 78:533&#x2013;43. 10.1189/jlb.0804481</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0804481</ArticleId><ArticleId IdType="pubmed">15894585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Lee SS, Hou SM, Chiang BL. Polysaccharide purified from Ganoderma lucidum induces gene expression changes in human dendritic cells and promotes T helper 1 immune response in BALB/c mice. Mol Pharmacol. (2006) 70:637&#x2013;44. 10.1124/mol.106.022327</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.106.022327</ArticleId><ArticleId IdType="pubmed">16670374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. (2004) 78:7916&#x2013;24. 10.1128/JVI.78.15.7916-7924.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem. (1956) 28:350&#x2013;6. 10.1021/ac60111a017</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac60111a017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C, Hung WT, Kuo CY, Liao KS, Liu YC, Yang WB. I2-catalyzed oxidative condensation of aldoses with diamines: synthesis of aldo-naphthimidazoles for carbohydrate analysis. Molecules. (2010) 15:1340&#x2013;53. 10.3390/molecules15031340</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules15031340</ArticleId><ArticleId IdType="pmc">PMC6257232</ArticleId><ArticleId IdType="pubmed">20335985</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YT, Hung WT, Wang SH, Fang JM, Yang WB. Quantitative analysis of sugar ingredients in beverages and food crops by an effective method combining naphthimidazole derivatization and 1H-NMR spectrometry. Funct Foods Health Dis. (2017) 7:494&#x2013;510. 10.31989/ffhd.v7i7.348</Citation><ArticleIdList><ArticleId IdType="doi">10.31989/ffhd.v7i7.348</ArticleId></ArticleIdList></Reference><Reference><Citation>Viel S, Capitani D, Mannina L, Segre A. Diffusion-ordered NMR spectroscopy: a versatile tool for the molecular weight determination of uncharged polysaccharides. Biomacromolecules. (2003) 4:1843&#x2013;7. 10.1021/bm0342638</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bm0342638</ArticleId><ArticleId IdType="pubmed">14606917</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Chow YH, Huang LM, Hsieh SM, Cheng PY, Hu KC. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge. Sci Rep. (2018) 8:10713. 10.1038/s41598-018-28281-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28281-5</ArticleId><ArticleId IdType="pmc">PMC6048030</ArticleId><ArticleId IdType="pubmed">30013088</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou AT, Wu SY, Liao CC, Chang YS, Chang CS, Shih C. A new animal model containing human SCARB2 and lacking stat-1 is highly susceptible to EV71. Sci Rep. (2016) 6:31151. 10.1038/srep31151</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31151</ArticleId><ArticleId IdType="pmc">PMC4976353</ArticleId><ArticleId IdType="pubmed">27499235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. (2001) 20:895&#x2013;904. 10.1016/S0264-410X(01)00385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Solans L, Locht C. The role of mucosal immunity in pertussis. Front Immunol. (2018) 9:3068. 10.3389/fimmu.2018.03068</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03068</ArticleId><ArticleId IdType="pmc">PMC6339907</ArticleId><ArticleId IdType="pubmed">30692990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Cheng PY, Chin CL, Huang LM, Lin SY, Chiang BL. Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine. Vaccine. (2018) 36:4331&#x2013;8. 10.1016/j.vaccine.2018.05.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.090</ArticleId><ArticleId IdType="pubmed">29891349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim S, Soh SH, Im YB, Ahn C, Park HT, Park HE, et al. Induction of systemic immunity through nasal-associated lymphoid tissue (NALT) of mice intranasally immunized with Brucella abortus malate dehydrogenase-loaded chitosan nanoparticles. PLoS One. (2020) 15:e0228463. 10.1371/journal.pone.0228463</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228463</ArticleId><ArticleId IdType="pmc">PMC7004331</ArticleId><ArticleId IdType="pubmed">32027689</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. (2010) 10:778&#x2013;90. 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, Chen SH. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol. (2009) 83:6477&#x2013;83. 10.1128/JVI.00434-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00434-09</ArticleId><ArticleId IdType="pmc">PMC2698549</ArticleId><ArticleId IdType="pubmed">19386699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu MJ, Lee SS, Lin WW. Polysaccharide purified from Ganoderma lucidum inhibits spontaneous and Fas-mediated apoptosis in human neutrophils through activation of the phosphatidylinositol 3 kinase/Akt signaling pathway. J Leukoc Biol. (2002) 72:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">12101282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu MJ, Lee SS, Lee ST, Lin WW. Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from Ganoderma lucidum. Br J Pharmacol. (2003) 139:289&#x2013;98. 10.1038/sj.bjp.0705243</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0705243</ArticleId><ArticleId IdType="pmc">PMC1573843</ArticleId><ArticleId IdType="pubmed">12770934</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacca M, Bohme J, Zambetti LP, Khameneh HJ, Paleja BS, Laudisi F, et al. NLRP10 enhances CD4(+) T-cell-mediated IFNgamma response via regulation of dendritic cell-derived IL-12 release. Front Immunol. (2017) 8:1462. 10.3389/fimmu.2017.01462</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01462</ArticleId><ArticleId IdType="pmc">PMC5673625</ArticleId><ArticleId IdType="pubmed">29163529</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi P, Behzadi E, Ranjbar R. IL-12 family cytokines: general characteristics, pathogenic microorganisms, receptors, and signalling pathways. Acta Microbiol Immunol Hung. (2016) 63:1&#x2013;25. 10.1556/030.63.2016.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/030.63.2016.1.1</ArticleId><ArticleId IdType="pubmed">27020866</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu HY, Hua KF, Lin CC, Lin CH, Hsu J, Wong CH. Extract of Reishi polysaccharides induces cytokine expression via TLR4-modulated protein kinase signaling pathways. J Immunol. (2004) 173:5989&#x2013;99. 10.4049/jimmunol.173.10.5989</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.10.5989</ArticleId><ArticleId IdType="pubmed">15528333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Ding R, Jiang S, Ji L, Pan M, Liu L, et al. The adjuvanticity of Ganoderma lucidum polysaccharide for newcastle disease vaccine. Int J Biol Macromol. (2014) 65:431&#x2013;5. 10.1016/j.ijbiomac.2014.01.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2014.01.067</ArticleId><ArticleId IdType="pubmed">24530324</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. (2005) 58:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. (2005) 79:2910&#x2013;9. 10.1128/JVI.79.5.2910-2919.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.5.2910-2919.2005</ArticleId><ArticleId IdType="pmc">PMC548446</ArticleId><ArticleId IdType="pubmed">15709010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>